{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:29:56Z","timestamp":1707524996124},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"DOI":"10.7759\/cureus.37919","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T10:37:32Z","timestamp":1682073452000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapy-Related Acute Promyelocytic Leukemia Developed During Pembrolizumab Therapy"],"prefix":"10.7759","author":[{"given":"Cecily E","family":"Ober","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E","family":"Jacocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B","family":"Osswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Successful treatment of therapy-related acute promyelocytic leukemia with all-trans-retinoic acid following epirubicin for hepatocellular carcinoma and docetaxel and pembrolizumab therapies for lung carcinoma: a triple malignancy case","volume":"45","author":"Suzuki R","year":"2020","unstructured":"Suzuki R, Kawai H, Furuya D, Akashi H, Ogawa Y, Kawada H, Ando K. Successful treatment of therapy-related acute promyelocytic leukemia with all-trans-retinoic acid following epirubicin for hepatocellular carcinoma and docetaxel and pembrolizumab therapies for lung carcinoma: a triple malignancy case. Tokai J Exp Clin Med. 2020, 45:92-6.","journal-title":"Tokai J Exp Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPE0MV0YTWLUUE","article-title":"Clinical and pathologic features of secondary acute promyelocytic leukemia","volume":"137","author":"Duffield AS","year":"2012","unstructured":"Duffield AS, Aoki J, Levis M, et al.. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol. 2012, 137:395-402. 10.1309\/AJCPE0MV0YTWLUUE","journal-title":"Am J Clin Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0625-5","article-title":"Therapy-related acute promyelocytic leukemia: a systematic review","volume":"30","author":"Rashidi A","year":"2013","unstructured":"Rashidi A, Fisher SI. Therapy-related acute promyelocytic leukemia: a systematic review. Med Oncol. 2013, 30:625. 10.1007\/s12032-013-0625-5","journal-title":"Med Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.072","article-title":"Therapy-related acute promyelocytic leukemia","volume":"21","author":"Beaumont M","year":"2003","unstructured":"Beaumont M, Sanz M, Carli PM, et al.. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003, 21:2123-37. 10.1200\/JCO.2003.09.072","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147%2FCMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data","volume":"11","author":"du Rusquec P","year":"2019","unstructured":"du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019, 11:4297-312. 10.2147%2FCMAR.S151023","journal-title":"Cancer Manag Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE- 057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar AV","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, et al.. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE- 057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncology. 2021, 22:919-30. 10.1016\/S1470-2045(21)00147-9","journal-title":"Lancet Oncology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer R","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A, et al.. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer. 2021, 147:170-81. 10.1016\/j.ejca.2021.01.013","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch GE","year":"2021","unstructured":"Koch GE, Smelser WW, Chang SS. Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them. Urology. 2021, 149:11-20. 10.1016\/j.urology.2020.10.039","journal-title":"Urology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan JM","year":"2006","unstructured":"McKiernan JM, Masson P, Murphy AM, et al.. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006, 24:3075-80. 10.1200\/JCO.2005.03.1161","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03230-4","article-title":"Hematologic malignancies following immune checkpoint inhibition for solid tumors","volume":"72","author":"van Eijs MJ","year":"2023","unstructured":"van Eijs MJ, van der Wagen LE, Mous R, et al.. Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer Immunol Immunother. 2023, 72:249-55. 10.1007\/s00262-022-03230-4","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/138124-therapy-related-acute-promyelocytic-leukemia-developed-during-pembrolizumab-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:52Z","timestamp":1707508792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/138124-therapy-related-acute-promyelocytic-leukemia-developed-during-pembrolizumab-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.37919","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}